Idoxifene, a tissue-specific selective estrogen receptor modulator, was evaluated in male and female rats and female rabbits after oral administration for effects on fertility and/or embryo-fetal development. In all studies, adult toxicity was evident at doses &0.03 mg/ kg/day in rats and ^0.1 mg/kg/day in rabbits as evidenced by decreased body weight and/or food consumption. In the male fertility study, rats were treated with 0.003,03, or 3.0 mg/kg/day for 64 to 68 days. Doses ^03 mg/kg/day decreased seminal vesicle and prostate weights and impaired posttesticular sperm development, resulting in decreased epididymal sperm count and weight, but did not affect male fertility. In the female fertility study, rats were treated for 2 weeks prior to mating until insemination with 0.003, 0.03, or 3.0 mg/kg/day. Disrupted estrous cycles, impaired fertility, increased preimplantation loss, and increased vaginal fluid at necropsy were evident at &0.03 mg/kg/day. In the early embryonic development study, pregnant female rats were treated from days 0 to 6 postcoitus (pc) with 0.003, 0.03, or 3.0 mg/kg/day idoxifene. Partial or complete preimplantation loss was seen at 0.03 and 3.0 mg/kg/day, respectively. In the embryo-Jetal development study, pregnant rats were treated from days 6 to 17 pc with 0.003,0.03, or 3.0 mg/kg/day. At 3.0 mg/kg/day there was maternal lethality, excess vaginal fluid, embryofetal death, generalized fetal edema, and developmental delays. Excess vaginal fluid but no fetal effects were seen at 0.03 mg/kg/day. There were no treatment-related effects at 0.003 mg/kg/day in any rat reproduction study performed. In the rabbit embryo-fetal development study, pregnant New Zealand White rabbits were treated from days 6 to 20 pc with 0.01, 0.1, or 1.0 mg/kg/day idoxifene. At 1.0 mg/kg/day there was maternal lethality, vaginal or uterine bleeding, abortion/premature deliveries, and embryolethality. Vaginal or uterine bleeding was seen at 0.1 mg/kg/day. No treatment-related effects were observed at 0.01 mg/kg/day. Although systemic toxicity was evident in all the studies, the effects of idoxifene on rat and rabbit reproduction were considered to be due to the pharmacological activity of the compound, c 1998 soda? of Toxi col ogy.
Idoxifene ((£> 1 -[2-[4-[ 1 -(4-iodophenyl) -2-phenyl-1 -butenyl]-' phenoxy]ethyl] pyrrolidine) is a novel selective estrogen receptor modulator (SERM) being developed for the treatment of advanced breast cancer and prevention of postmenopausal osteoporosis (Coombes et al., 1995) . Idoxifene acts in breast tissue (human MCF-7 cancer cells) as an estrogen antagonist through the same estrogen response element as the natural steroid hormone (Nuttal et al, 1997) . It binds to the estrogen receptor in breast tissue 2.5 to 5 times more strongly than does tamoxifen (McCague et al, 1989; Chander et al., 1991) , and inhibits the growth of human MCF-7 breast cancer xenografts (Johnston et al, 1997) .
In bone, idoxifene works as an estrogen agonist in osteoblasts through interaction of the osteoblast estrogen receptor with classic estrogen response elements (Nuttall et al, 1997) . In osteoclasts, like estrogen, idoxifene is capable of stimulating apoptosis (Nuttall et al, 1997) . Bone loss was prevented in the ovariectomized rat osteoporosis model and there was an estrogen-like effect of lowering serum cholesterol (Bradbeer et al, 1996) .
Tamoxifen and other compounds considered to be SERMs have been shown to have multiple reproductive effects in several species including rat, rabbit, dog, and monkey. Such effects are expected given the importance of estrogen in several reproductive processes including estrus cyclicity, ovulation, and implantation (Huet and Dey, 1987; Moudgal and Ravindranath, 1989; Furr et al, 1979; Tucker et al, 1984; Singh et al, 1994; Barnes and Meyer, 1962; Callantine et al, 1966; Knobil and Neill, 1988) .
The studies presented in this paper were undertaken to investigate the effect of idoxifene, when administered by oral gavage to adult animals, on male and female rat fertility and rat and rabbit embryo-fetal development.
MATERIALS AND METHODS
Animals and husbandry. All rats were Sprague-Dawley, were virusantibody-free (Charles River Laboratories, Raleigh NC), and were approximately 10 weeks of age at study start. Following an acclimation period, the rats were individually housed in stainless-steel cages (except during cohabitation) in rooms maintained at 72 ± 4°F, 40-70% relative humidity with a 12-h light/dark cycle. Individual mated females were housed in clear polycarbonate TREINEN, REHM, AND W1ER boxes. Food (Certified Rodent Chow No. 5002 , PMI, St. Louis MO) and filtered tap water were available ad libitum. For mating, each female/male was housed with one untreated male/female, respectively, of the same strain and the females were checked daily for the presence of sperm in a vaginal lavage. The day that sperm were found in the vaginal lavage was considered day 0 postcoitus (pc). Time-mated New Zealand White rabbits (HRP, Inc., Denver PA), approximately 6 months old, were used. The rabbits were individually housed in stainless-steel cages in rooms maintained at 68 ± 4°F, 40-60% relative humidity with a 12-h light/dark cycle. The rabbits were offered 125 g/day of food (certified Lab Rabbit Chow No. HF5322, PMI Feeds, Inc., St Louis, MO) and filtered tap water ad libitum. All animals were checked daily for changes in appearance, behavior, mortality, and evidence of abortion. Body weights and food consumption were measured at various times throughout the studies including pretreatment, treatment, and posttreatment periods.
Test article. Stock solutions (10 or 20 mg/mL) of idoxifene in an aqueous lactate (0.1 Mydextrose (248 mM) vehicle were prepared as appropriate for stability data. Dosing solutions were prepared by serial dilution of the stock solutions with vehicle and administered by oral gavage at dosing volumes of 10 mL/kg (rats) or 5mL/kg (rabbits). Control animals received vehicle only at equivalent dosing volumes.
Due to possible adherence of test article to glass, measured concentrations of drug in the rat studies ranged from 27 to 42% of nominal for the 0.0003 mg/mL concentration, 64 to 80% of nominal for the 0.003 mg/mL concentration, 82 to 89% of nominal for the 0.03 mg/mL concentration, and 96 to 102% of nominal for the 0.3 mg/mL concentration. Tween 80 (0.05%) was added to the lactate/dextrose buffer for the rabbit embryo-fetal development study and the measured concentrations were 98-106% of the theoretical value for all concentrations.
Male fertility study. This study was conducted to assess the potential reproductive toxicity of idoxifene when administered to male rats up to 68 days.
Idoxifene was administered to 25 males/group at dosage levels of 0.003, 0.3, or 3 mg/kg/day. After 28 days of treatment, the males were cohabited 1:1 up to 14 days with untreated females. Cesarean section of the mated females and subsequent fetal examinations were the same as those described for the female fertility study.
After 64-68 days of treatment the males were necropsied and the left testis, left epididymis, ventral prostate, and left seminal vesicle from each male were weighed. The right testis parenchyma and cauda epididymis for each male were weighed and frozen. Frozen testis parenchyma and frozen cauda epididymis were homogenized for 2 min in 20 mL cold 0.9% sodium chloride containing 0.05% Triton X-100 with a Tekmar Tissumizer. Homogenization-resistant spermatids and spermatozoa, respectively, were counted in a hemocytometer. Spermatozoa were collected at necropsy from the vas deferens into 30 mL of Dulbecco's phosphate-buffered saline containing 10 g/L bovine serum albumin and incubated for approximately 15 min at 37°C in a humidified carbon dioxide atmosphere. A 0.0424-mL aliquot of the incubated specimen was placed on a polystyrene dish and a coverslip was applied to create a chamber approximately 50 /xM in depth. The specimen was transferred to a microscope stage maintained at 35 to 37°C and 15 fields were videorecorded by moving the stage micrometer in a predefined pattern. The videomicrograph system consisted of a Zeiss Model IM 35 inverted microscope with a Nikon 4X objective and pseudodark field illumination equipped with a high-resolution video camera (Cryo Resources, New York). The videotape was analyzed for the numbers of motile and nonmotile spermatozoa using a CellSoft Series 4000 computerassisted sperm analysis (CASA) system (Cryo Resources).
Fertility study in female rats. This study was conducted to assess the potential reproductive effects of idoxifene when administered to female rats for 14 days prior to mating and during mating until insemination.
Idoxifene was administered to 25 females per group at dosage levels of 0.003, 0.03, or 3 mg/kg/day. Vaginal smears were evaluated daily for stage of estrus for 14 days prior to treatment, during 14 days of treatment preceding mating, and during the mating period. Mating was 1:1 with untreated males for a maximum of 14 days. All females were euthanized by carbon dioxide asphyxiation and cesarean sectioned on day 21 pc. The numbers of live and dead fetuses, resorptions (early and late), and implantation sites were determined. The ovaries were examined and the corpora lutea counted. Fetuses were weighed, sexed, and examined externally.
Early embryonic development to implantation study in rats. This study was conducted to assess the effect of idoxifene on implantation and early embryonic development when administered to female rats from days 0 to 6 pc.
Idoxifene was administered to 46 females per group at dosage levels of 0.003,0.03, or 3 mg/kg/day. One-half of the mated females were killed on day 21 pc for cesarean section delivery as described for the female fertility study. The other half were allowed to deliver naturally to identify potential effects in gestation length secondary to delayed implantation. Pregnancy length was determined and the pups were assessed for viability, weighed, sexed, examined externally, and then killed.
Embryo-fetal development studies in rats and rabbits. These studies were conducted to assess the effect of idoxifene when administered orally to pregnant rats and rabbits during the period of organogenesis.
For the rat study, idoxifene was administered to 23 females/group at dosage levels of 0.003, 0.03, or 3 mg/kg/day from days 6 to 17 pc. Females were cesarean sectioned on day 21 pc as described for the female fertility studies In addition, approximately one-half of the fetuses underwent visceral examination (Staples, 1974 ) with Bouin's fixed heads examined after coronal sectioning (Wilson, 1965) . The remaining fetuses were examined for skeletal alterations after staining with Alizarin Red S.
For the rabbit study, time-mated rabbits (23/group) were orally administered 0.01, 0.1, or 1 mg/kg/day idoxifene on days 6-20 pc. Cesarean sections were performed on day 29 pc as described above. All fetuses were weighed, sexed, and examined for external, internal, and skeletal anomalies as described for the rat embryo-fetal development study with the exception of fresh eye and brain morphology evaluations.
Statistical methods. Quantitative variables were analyzed using either the parametric ANOVA followed by a pairwise comparison using Dunnett's test (Milliken and Johnson, 1984 ; SAS/STAT User's Guide; Dunnett, 1965) or a nonparametric Kruskal-Wallis test followed by a pairwise comparison method of Conover (Conover, 1965 ) using a Bonferroni correction to maintain an overall a level of 5%. The pairwise methods were used only when the overall ANOVA F test or the Kruskal-Wallis test was significant at an a level of 5%. Choice between the parametric and nonparametric methods was based on checks for certain parametric assumptions which were carried out using the Wilks-Shapiro (Shapiro and Wilk, 1965; Royston, 1982) and Levene test (Milliken and Johnson, 1984) . Both tests were performed using a 1% significance level. The variables analyzed by this method include body weight, body weight changes, rat food consumption, organ weights, sperm count and motility, gravid uterine weight, and number of days needed for mating. Based on historical data, nonparametric methods were used for corpora lutea, implantations, resorptions, and dead or live fetuses/litter data. Binary variables (including mating incidence, pregnancy incidence, estrous cycle data, and incidence of external fetal observations and quantitative variables transformed into a binary scale (including food consumption data for rabbits) were analyzed using the Cochran-Armitage test (Agresti, 1990 ) which tests for a dose-response relationship between the incidence proportion and dose level.
The fetal weight data were analyzed using the nested analysis of variance to account for the correlation between fetal weights for pups nested within litters.
Unless otherwise noted, all other statistical tests were performed at a level of 5%. Where appropriate, the data are expressed as mean ± SEM. (Table 1) There were no drug-related mortality, clinical signs, or necropsy findings. Drug-related decreases in mean body weight began during the second week of treatment and continued until termination among males given 3.0 mg/kg/day (7 to 25% less) and 0.3 mg/kg/day (6 to 19% less) idoxifene when compared to controls. Body weight gain between day 1 and termination was less than that of controls by 58% for the 0.3 mg/kg/day group and 79% for the 3.0 mg/kg/day group. Food consumption was significantly decreased throughout the study for the 0.3 mg/kg/ day (14 to 17% less) and the 3.0 mg/kg/day (17 to 23% less) groups when compared to controls (data not shown).
RESULTS

Male Fertility Study in Rats
There was no drug-related effect on mating incidence, mean days needed for mating, or pregnancy incidence. At 0.3 and 3.0 mg/kg/day, absolute seminal vesicle (45 and 55% less, respectively) and ventral prostate (31 and 44% less, respectively) weights were significantly less than controls. Left epididymis weight was also decreased from controls at 0.3 and 3.0 (13 and 15% less, respectively), which is consistent with reduced epididymal sperm count, whereas testis weight was not affected. There was a significant decrease in the number of sperm cells per cauda epididymis at 0.3 mg/kg/day (20% less) and 3.0 mg/kg/day (28% less), but there was no effect on number of sperm cells/g cauda or spermatids per testis. The percentage of sperm cells which were motile was not different among the groups.
There were no significant differences in the numbers of corpora lutea, implantations, resorptions, or dead or live fetuses/-litter, or in gravid uterine weight No drug-related effect on fetal body weight was observed and detailed fetal external examination revealed no effects attributable to male (F0) treatment.
No drug-related effects were detected at 0.003 mg/kg/day.
Female Fertility Study in Rats (Table 2)
There were no drug-related deaths. Females in the 3 mg/kg/ day group lost 3-4 g of body weight weekly during the premating period which resulted in mean body weight which was 6% less than controls at mating. Since there were no pregnant females at 3 mg/kg/day, gestational body weights were not determined for this group. Doses <0.03 mg/kg/day did not affect body weight during treatment; however, decreased body weight gain (29-37% less than control) during the last week of gestation occurred at 0.03 mg/kg/day. This resulted in day 21 pc body weights 9% less than controls. This effect was attributed to decreased uterine content weight since day 21 pc body weights corrected for gravid uterus weight were not different. Food consumption during premating drug treatment was less than controls by up to 9% at 0.03 mg/kg/day and 15% at 3.0 mg/kg/day (data not shown).
Idoxifene caused female rats (7/25) in the 0.03 mg/kg/day group to have extended periods of diestrus (24 consecutive days) while the 3.0 mg/kg/day group was acyclic after five doses. A significant decrease in mating incidence was seen at 3.0 mg/kg/day (72 versus 92% for control); however, the time needed for mating was not affected at any dose of idoxifene. Of the females that mated, a significant decrease in pregnancy incidence was seen at 0.03 and 3.0 mg/kg/day (71 and 0%, respectively), compared to control (100%). At necropsy, excess mucinous fluid (red, brown, yellow, or green) was observed in the vaginas of 4/25 females at 0.03 mg/kg/day and 8/25 females at 3.0 mg/kg/day. This finding was seen in both pregnant and nonpregnant females. There were no pregnant females in the 3.0 mg/kg/day group, indicating complete preimplantation loss. The 0.03 mg/kg/ day group relative to controls had 16% fewer corpora lutea/ dam and 42% fewer implantations/litter associated with a 3.5-fold higher preimplantation loss of embryos, which resulted in a 50% smaller litter size. Although the percentage of implants resorbed was apparently large at 0.03 mg/kg/day (30.8 vs 11.1% for control), it was not statistically significant. Moreover, the total number of resorptions/litter was comparable (2.2) to control (1.7), so the increase in percentage of implants resorbed was attributed to the small number of implants in the 0.03 mg/kg/day litters.
Fetal body weight at 0.03 mg/kg/day was significantly less than controls by 11%. One litter from the 0.03 mg/kg/ day group had viable fetuses developmentally consistent (weight and external morphology) with day 13-15 pc fetuses, indicating possible delayed implantation. Detailed fetal external examinations revealed no drug-related effects.
There were no drug-related effects detected at 0.003 mg/kg/day. (Table 3) There were no drug-related deaths, clinical signs, or necropsy findings. Females in the 0.03 mg/kg/day group had significantly reduced gestational weight gain (31% less than control) during drug treatment. Food consumption during the treatment period was 6% less than controls for the 0.03 mg/ kg/day females (data not shown).
Early Embryonic Development to Implantation Study in Rats
There were no pregnant females at term in the 3.0 mg/ kg/day group, indicating complete preimplantation loss. The 0.03 mg/kg/day groups had 9 to 26% fewer implantations/ litter than controls, which was associated with a 1.6-to 2.8-fold higher preimplantation loss of embryos and 9 to 27% fewer live fetuses/litter. Gestation length was not affected, indicating that implantation was not significantly delayed at <0.03 mg/kg/day.
There were no drug-related effects detected at 0.003 mg/kg/day.
Embryo-Fetal Development Study in Rats (Tables 4,5)
Nine drug-related deaths occurred in the 3.0 mg/kg/day group between days 19 and 21 pc. Mean body weight among females given 3.0 mg/kg/day was significantly less than controls by 5 to 18% during days 8 to 21 pc. Day 21 maternal body weight minus gravid uterus weight was also significantly decreased by 18% for the 3.0 mg/kg/day group versus control. Food consumption was significantly less than controls for the 0.03 mg/kg/day (5% less) and 3.0 mg/kg/day (30% less) groups from days 6 to 18 pc. At necropsy, 12 of 21 pregnant females in the 3.0 mg/kg/day group had enlarged adrenals (data not shown).
The numbers of corpora lutea and implantations were not significantly affected by drug treatment. A significant increase in the number of early and late resorptions was seen at 3.0 mg/kg/day (32.2% implants resorbed versus 7.0% in control) which was associated with a decreased litter size (9.8 live fetuses/litter versus 14.3 in control).
There was no significant effect on fetal body weight. There was no significant increase in the mean percentage of fetuses per litter with malformations (total incidence), or in the proportion of litters with at least one malformed fetus. However, there was a significant increase in the number of litters at 3.0 mg/kg/day with generalized fetal edema (3/12) compared to control (0/23). Other fetal observations with an increased incidence at 3.0 mg/kg/day were cervical rib, sternebrae varied in shape, knobby and wavy ribs, and incompletely ossified femur, ribs, lumbar vertebrae, jugal, supraoccipital, premaxilla, parietal, and interparietal.
Embryo-Fetal Development Study in Rabbits (Table 6)
One drug-related death occurred in a 1.0 mg/kg/day female on day 28 pc during premature delivery. The female had negligible food consumption for 12 of 14 days preceding death and two additional fetuses were found in the vagina at necropsy.
Mean body weight for the 1.0 mg/kg/day females was 9% less than controls at necropsy and decreased body weight gain was seen from days 6 to 20 pc for the 1.0 (41% of control) and 0.1 (55% of control) mg/kg/day groups. Food consumption was significantly less than controls by up to 40% for the 1.0 mg/kg/day group during days 8 to 29 pc (data not shown).
Presumptive utero-vaginal bleeding was seen on days 15 to 15.9 ± 0.6 14.8 ± 0.8 6.5 ± 4.0 3.6 ± 1.0* 1.3 ±0.6* 32.2 ± 5.9* 9.8 ± 1.0* 5.02 ± 0.36 5.14 ± 0.30 29 pc in 2/23 and 18/23 females from the 0.1 and 1.0 mg/kg/ day groups, respectively. There was evidence of partial or complete abortion/premature delivery for 1, 0, 0, and 6 does in the 0, 0.01, 0.1, and 1.0 mg/kg/day groups, respectively, indicating that bleeding was not necessarily indicative of abortion or premature delivery. Two does given 1.0 mg/kg/day idoxifene also had nonviable (completely resorbed) litters resulting in a decreased number of females with live fetuses at term in the 1.0 mg/kg/day group (16/21 versus 21/22 in control). A significant increase in the number of early and late resorptions was seen at 1.0 mg/kg/day (31.3% implants resorbed versus 4.1% in control) which was associated with a 12% decrease in litter size. There was no drug-related effect on fetal body weight. There was no increase in the mean percentage of fetuses per litter with malformations (total incidence) or in the proportion of litters with at least one malformed fetus. There was a significant increase in the numbers of litters having a fetus with one or more sternebrae not evident in the absence of fetal body weight effects.
There were no drug-related effects detected at 0.01 mg/ kg/day.
DISCUSSION
Male and female adult toxicity was evidenced by decreased body weight and/or food consumption at doses 5:0.03 mg/kg/ day in rats and &0.1 mg/kg/day in rabbits. This may in part be due to the estrogenic activity of idoxifene, probably due to enhancement of somatostatin-mediated suppression of growth hormone secretion (Tannenbaum et al, 1992) .
In the male fertility study, idoxifene decreased accessory sex organ weights and epididymal sperm count, which resulted in a decrease in epididymal weight. There were no apparent effects on testicular spermatogenesis, mating parameters, or fertility. Similar accessory sex organ weight effects have also been seen with estrogen (Robaire et ai, 1979 ) and a structurally similar SERM, tamoxifen (Furr et ai, 1979) ; however, decreased testis weight was also observed with tamoxifen at higher doses. Although epididymal sperm count and weight were decreased, sperm motility and count were sufficient to sustain normal fertility. The effects on epididymal sperm counts and weight seen in this study were not likely due to decreased body weight since rats maintained at 70% of ad libitum body weights had normal cauda epididymis sperm counts and weights (Chapin et ai, 1993) . Potential mechanisms of the decreased accessory sex organ weights by idoxifene include antagonism at the androgen receptor, impairment of pituitary gonadotropin production, and direct effects on the target organs. This effect is not likely due to an interaction with the androgen receptor since tamoxifen did not affect accessory sex organ growth in castrated male rats supplemented with exogenous androgen (Furr and Jordan, 1984) . This effect may be caused by estrogen agonist activity of idoxifene at the hypothalamus-pituitary axis (inhibition of luteinizing hormone levels), or on the testis itself (direct inhibition of testosterone production). Tamoxifen has been shown to decrease plasma levels of luteinizing hormone and testosterone after 5 and 9 days of administration (Bartke et ai, 1978; Lacroix et ai, 1987) . Tamoxifen, however, has also been shown to have a direct effect on Leydig cell (Lin et ai, 1981) and whole testis (Bartke et al., 1978) production of testosterone in vitro.
In the female fertility study, a decrease in corpora lutea number was seen at 0.03 mg/kg/day. This is consistent with the findings of a 28-day toxicity study in rats where retained tertiary follicles were seen in 9/10 females at 1 mg/kg/day idoxifene. Likewise, tamoxifen has been shown to inhibit ovulation in the rat, and a decrease in corpora lutea was seen in a 3-month toxicity study with 2 mg/kg/day tamoxifen (Tucker et al., 1984) . Persistent diestrus was also seen with other SERMs. Tamoxifen blocked vaginal cornification by estradiol when they were administered concomitantly (Tucker et al., 1984) , and raloxifene has been reported to disrupt estrus cyclicity in rats (Hoyt et ai, 1996) . Although LH and estrogen levels were not determined in this study, it is possible that ovarian estradiol levels were decreased by idoxifene, resulting in persistent diestrus and inhibition of the LH surge necessary for ovulation. Although the mating incidence for the 3.0 mg/kg/day group was decreased, several of the females mated despite persistent diestrus, and the time to mate was normal for these animals. In spite of persistent diestrus, idoxifene may also be acting centrally as an estrogen agonist to induce lordosis and mating behavior in these females since estrogen has been shown to affect sexual behavior in rats (Pfaff and Schwartz-Giblin, 1988) . Implantation number was decreased at 0.03 and absent at 3.0 mg/kg/day due in part to increased preimplantation loss. This effect was likely due to inhibition of the implantation process itself. Delayed or inhibited implantation has been a consistent finding reported with tamoxifen as well as other antiestrogenic compounds (Huet and Dey, 1987; Tucker et ai, 1984; Singh et ai, 1994; Callantine et ai, 1966; Harper and Walpole, 1967; Watson and Alam, 1976; Clarke et ai, 1996) . Although in this study idoxifene was administered up to the day of insemination and not during the period of implantation, the half-life of idoxifene is 2 to 3 days and sufficient residual compound to inhibit implantation was likely available, given the sensitivity of implantation to antiestrogenic effects.
In the early embryonic development study, females were treated on days 0 to 6 pc and were either cesarean sectioned or allowed to naturally deliver. This design would have allowed for detection of significantly delayed implantation. In this study, complete inhibition but no significant delay of implantation was observed. Fetal weights were decreased, however, similar to the fertility study, indicating that a subtle delay in implantation may have occurred. Raloxifene dosed on days 0 to 5 pc both inhibited and delayed implantation (Clarke et ai, 1996) . The reason for the low incidence of significantly delayed implantation (one dam in fertility study only) with idoxifene compared to raloxifene is unknown but may be due to the relative potencies of the two compounds for effects on implantation.
Mortality and vaginal bleeding were seen in the rat embryofetal development study during days 18 to 21 pc. The cause of death is not known since findings at necropsy were limited to increased adrenal size and organ histology was not performed. In a 1-month toxicity study, mortality was not seen at 3.0 mg/kg/day, but was seen at 10 mg/kg/day. Whether the animals in this study were more susceptible to idoxifene due to the altered physiology of late pregnancy is not known. Embryolethality was seen at 3.0 mg/kg/day. This effect was not specific to a given stage of embryo-fetal development since an increase in both early and late resorptions was seen. Developmental toxicity was also evidenced by an increase in generalized fetal edema and incomplete ossifications of several skeletal structures and wavy ribs. These findings are consistent with those reported after tamoxifen administration to pregnant rats (Tucker et ai, 1984) . Rib effects and ossification delays of this nature are not considered to be permanent (Nishimura et ai, 1982) and were shown not to be present by day 14 postpartum in the case of tamoxifen (Tucker et ai, 1984) . Similar effects (fetal runts and wavy ribs) were also seen with raloxifene (Byrd and Francis, 1996) .
Vaginal/uterine bleeding was seen at 0.1 and 1.0 mg/kg/day idoxifene in the rabbit embryo-fetal development study. Abortions/premature delivery occurred at 1.0 mg/kg/day. In several cases, food consumption was not affected prior to the abortions/early deliveries, indicating that they did not likely occur due to restricted food intake, which can be a cause of abortion in rabbits (Matsuzawa, 1981) . Similar to the rat embryo-fetal development study, an increase in early and late resorptions was also seen in the rabbits at 1.0 mg/kg/day. Of the fetuses that survived, only an increase in the numbers of litters having a fetus with one or more sternebrae not evident was observed. These results are consistent with those seen with tamoxifen given to pregnant rabbits. Tamoxifen (2 mg/kg/day) given from day 10 pc to parturition caused an increase in fetal resorptions, early deliveries, and uterine bleeding between days 23 and 26 pc (Furr et al, 1976) , and pregnant rabbits given 0.125 mg/kg/day tamoxifen aborted/prematurely delivered with no teratogenic findings observed (Physician's Desk Reference, 1995) . Tamoxifen has been shown to antagonize the luteotropic effect of estrogen in rabbits. Treatment with 2 mg/kg/day tamoxifen from days 10 to 20 resulted in an increase in embryonic loss while administration during days 20 to 30 of pregnancy resulted in premature parturition/abortion. Both of the effects were associated with a significant reduction in plasma progesterone without any effect on plasma estradiol (Labhesetwar, 1971) . Estradiol and progesterone levels were not determined in this study.
Depending on the endpoint, the pharmacologic effects of idoxifene were likely estrogenic (decreased accessory sex organ weights in males; decreased FO body weight; lordosis), antiestrogenic (implantation inhibition, inhibition of ovulation; persistent diestrus, rabbit abortions), or unknown (late maternal mortality in embryo-fetal development study, developmental delays, vaginal bleeding; resorptions) in nature and occurred in female rats, male rats, and rabbits at >0.03, 0.3, and 1.0 mg/kg/day, respectively. No drug-related reproductive effects were observed at 0.003 mg/kg/day in rats and 0.1 mg/kg/day in rabbits.
